Does the media favor PCRX or ZNTL?

In the previous week, Zentalis Pharmaceuticals had 3 more articles in the media than Pacira BioSciences. MarketBeat recorded 5 mentions for Zentalis Pharmaceuticals and 2 mentions for Pacira BioSciences. Pacira BioSciences' average media sentiment score of 1.66 beat Zentalis Pharmaceuticals' score of 0.71 indicating that Pacira BioSciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pacira BioSciences 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Zentalis Pharmaceuticals 1 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings & valuation, ZNTL or IVA?

Zentalis Pharmaceuticals has higher revenue and earnings than Inventiva. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Zentalis Pharmaceuticals $67.43M 4.37 -$137.06M -$1.95 N/A Inventiva $5.07M 198.29 -$400.67M N/A N/A

Is ZNTL or IVA more profitable?

Inventiva's return on equity of 0.00% beat Zentalis Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Zentalis Pharmaceuticals N/A -70.18% -51.46% Inventiva N/A N/A N/A

Does the media prefer ZNTL or IVA?

In the previous week, Inventiva had 3 more articles in the media than Zentalis Pharmaceuticals. MarketBeat recorded 8 mentions for Inventiva and 5 mentions for Zentalis Pharmaceuticals. Zentalis Pharmaceuticals' average media sentiment score of 0.71 beat Inventiva's score of 0.13 indicating that Zentalis Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zentalis Pharmaceuticals 1 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Inventiva 1 Very Positive mention(s) 0 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor ARDX or ZNTL?

In the previous week, Ardelyx had 1 more articles in the media than Zentalis Pharmaceuticals. MarketBeat recorded 6 mentions for Ardelyx and 5 mentions for Zentalis Pharmaceuticals. Zentalis Pharmaceuticals' average media sentiment score of 0.71 beat Ardelyx's score of 0.65 indicating that Zentalis Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ardelyx 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Zentalis Pharmaceuticals 1 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is HELP or ZNTL more profitable?

Zentalis Pharmaceuticals' return on equity of -70.18% beat Cybin's return on equity. Company Net Margins Return on Equity Return on Assets Cybin N/A -71.78% -64.81% Zentalis Pharmaceuticals N/A -70.18% -51.46%

Does the media favor HELP or ZNTL?

In the previous week, Cybin and Cybin both had 5 articles in the media. Cybin's average media sentiment score of 0.93 beat Zentalis Pharmaceuticals' score of 0.71 indicating that Cybin is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cybin 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Zentalis Pharmaceuticals 1 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Zentalis Pharmaceuticals (ZNTL) Competitors

$4.11 +0.34 (+9.02%)

As of 09/3/2026 04:00 PM Eastern

Compare

ZNTL vs. PCRX, IVA, ARDX, HELP, and AMPH

Should you buy Zentalis Pharmaceuticals stock or one of its competitors? Zentalis Pharmaceuticals's main competitors and comparable companies include Pacira BioSciences (PCRX), Inventiva (IVA), Ardelyx (ARDX), Cybin (HELP), and Amphastar Pharmaceuticals (AMPH). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Zentalis Pharmaceuticals compare to Pacira BioSciences?

Pacira BioSciences (NASDAQ:PCRX) and Zentalis Pharmaceuticals (NASDAQ:ZNTL) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, profitability, analyst recommendations, valuation, institutional ownership, media sentiment, dividends and risk.

Pacira BioSciences has a net margin of 1.96% compared to Zentalis Pharmaceuticals' net margin of 0.00%. Pacira BioSciences' return on equity of 9.68% beat Zentalis Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pacira BioSciences	1.96%	9.68%	5.30%
Zentalis Pharmaceuticals	N/A	-70.18%	-51.46%

Pacira BioSciences has higher revenue and earnings than Zentalis Pharmaceuticals. Zentalis Pharmaceuticals is trading at a lower price-to-earnings ratio than Pacira BioSciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pacira BioSciences	$726.41M	1.46	$7.03M	$0.35	76.00
Zentalis Pharmaceuticals	$67.43M	4.37	-$137.06M	-$1.95	N/A

99.7% of Pacira BioSciences shares are owned by institutional investors. 6.4% of Pacira BioSciences shares are owned by company insiders. Comparatively, 3.8% of Zentalis Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Pacira BioSciences currently has a consensus price target of $30.20, suggesting a potential upside of 13.53%. Zentalis Pharmaceuticals has a consensus price target of $6.75, suggesting a potential upside of 64.23%. Given Zentalis Pharmaceuticals' higher possible upside, analysts clearly believe Zentalis Pharmaceuticals is more favorable than Pacira BioSciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pacira BioSciences	0 Sell rating(s)	4 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.43
Zentalis Pharmaceuticals	1 Sell rating(s)	4 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.33

In the previous week, Zentalis Pharmaceuticals had 3 more articles in the media than Pacira BioSciences. MarketBeat recorded 5 mentions for Zentalis Pharmaceuticals and 2 mentions for Pacira BioSciences. Pacira BioSciences' average media sentiment score of 1.66 beat Zentalis Pharmaceuticals' score of 0.71 indicating that Pacira BioSciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pacira BioSciences	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Zentalis Pharmaceuticals	1 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Pacira BioSciences has a beta of 0.26, suggesting that its stock price is 74% less volatile than the broader market. Comparatively, Zentalis Pharmaceuticals has a beta of 1.85, suggesting that its stock price is 85% more volatile than the broader market.

Summary

Pacira BioSciences beats Zentalis Pharmaceuticals on 11 of the 16 factors compared between the two stocks.

How does Zentalis Pharmaceuticals compare to Inventiva?

Zentalis Pharmaceuticals (NASDAQ:ZNTL) and Inventiva (NASDAQ:IVA) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, valuation, risk, dividends, institutional ownership, media sentiment, profitability and analyst recommendations.

Inventiva's return on equity of 0.00% beat Zentalis Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zentalis Pharmaceuticals	N/A	-70.18%	-51.46%
Inventiva	N/A	N/A	N/A

Zentalis Pharmaceuticals presently has a consensus target price of $6.75, suggesting a potential upside of 64.23%. Inventiva has a consensus target price of $15.38, suggesting a potential upside of 217.67%. Given Inventiva's stronger consensus rating and higher possible upside, analysts clearly believe Inventiva is more favorable than Zentalis Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zentalis Pharmaceuticals	1 Sell rating(s)	4 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.33
Inventiva	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	3 Strong Buy rating(s)	3.10

Zentalis Pharmaceuticals has a beta of 1.85, indicating that its stock price is 85% more volatile than the broader market. Comparatively, Inventiva has a beta of 0.71, indicating that its stock price is 29% less volatile than the broader market.

In the previous week, Inventiva had 3 more articles in the media than Zentalis Pharmaceuticals. MarketBeat recorded 8 mentions for Inventiva and 5 mentions for Zentalis Pharmaceuticals. Zentalis Pharmaceuticals' average media sentiment score of 0.71 beat Inventiva's score of 0.13 indicating that Zentalis Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zentalis Pharmaceuticals	1 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Inventiva	1 Very Positive mention(s)	0 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

19.1% of Inventiva shares are held by institutional investors. 3.8% of Zentalis Pharmaceuticals shares are held by insiders. Comparatively, 32.0% of Inventiva shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Zentalis Pharmaceuticals has higher revenue and earnings than Inventiva.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zentalis Pharmaceuticals	$67.43M	4.37	-$137.06M	-$1.95	N/A
Inventiva	$5.07M	198.29	-$400.67M	N/A	N/A

Summary

Inventiva beats Zentalis Pharmaceuticals on 10 of the 14 factors compared between the two stocks.

How does Zentalis Pharmaceuticals compare to Ardelyx?

Ardelyx (NASDAQ:ARDX) and Zentalis Pharmaceuticals (NASDAQ:ZNTL) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, earnings, valuation, media sentiment, analyst recommendations, dividends, risk and institutional ownership.

In the previous week, Ardelyx had 1 more articles in the media than Zentalis Pharmaceuticals. MarketBeat recorded 6 mentions for Ardelyx and 5 mentions for Zentalis Pharmaceuticals. Zentalis Pharmaceuticals' average media sentiment score of 0.71 beat Ardelyx's score of 0.65 indicating that Zentalis Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ardelyx	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Zentalis Pharmaceuticals	1 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Ardelyx presently has a consensus price target of $13.90, indicating a potential upside of 274.66%. Zentalis Pharmaceuticals has a consensus price target of $6.75, indicating a potential upside of 64.23%. Given Ardelyx's stronger consensus rating and higher possible upside, equities research analysts clearly believe Ardelyx is more favorable than Zentalis Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ardelyx	2 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.75
Zentalis Pharmaceuticals	1 Sell rating(s)	4 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.33

58.9% of Ardelyx shares are held by institutional investors. 5.3% of Ardelyx shares are held by company insiders. Comparatively, 3.8% of Zentalis Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Ardelyx has a beta of 0.7, indicating that its share price is 30% less volatile than the broader market. Comparatively, Zentalis Pharmaceuticals has a beta of 1.85, indicating that its share price is 85% more volatile than the broader market.

Zentalis Pharmaceuticals has a net margin of 0.00% compared to Ardelyx's net margin of -12.35%. Ardelyx's return on equity of -36.00% beat Zentalis Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ardelyx	-12.35%	-36.00%	-10.77%
Zentalis Pharmaceuticals	N/A	-70.18%	-51.46%

Ardelyx has higher revenue and earnings than Zentalis Pharmaceuticals. Ardelyx is trading at a lower price-to-earnings ratio than Zentalis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ardelyx	$407.32M	2.27	-$61.60M	-$0.22	N/A
Zentalis Pharmaceuticals	$67.43M	4.37	-$137.06M	-$1.95	N/A

Summary

Ardelyx beats Zentalis Pharmaceuticals on 12 of the 17 factors compared between the two stocks.

How does Zentalis Pharmaceuticals compare to Cybin?

Cybin (NASDAQ:HELP) and Zentalis Pharmaceuticals (NASDAQ:ZNTL) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, profitability, media sentiment, valuation, risk, dividends and analyst recommendations.

Zentalis Pharmaceuticals' return on equity of -70.18% beat Cybin's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cybin	N/A	-71.78%	-64.81%
Zentalis Pharmaceuticals	N/A	-70.18%	-51.46%

Cybin has a beta of 0.63, suggesting that its share price is 37% less volatile than the broader market. Comparatively, Zentalis Pharmaceuticals has a beta of 1.85, suggesting that its share price is 85% more volatile than the broader market.

In the previous week, Cybin and Cybin both had 5 articles in the media. Cybin's average media sentiment score of 0.93 beat Zentalis Pharmaceuticals' score of 0.71 indicating that Cybin is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cybin	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Zentalis Pharmaceuticals	1 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

17.9% of Cybin shares are owned by institutional investors. 15.0% of Cybin shares are owned by company insiders. Comparatively, 3.8% of Zentalis Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Zentalis Pharmaceuticals has higher revenue and earnings than Cybin. Cybin is trading at a lower price-to-earnings ratio than Zentalis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cybin	N/A	N/A	-$148M	-$3.02	N/A
Zentalis Pharmaceuticals	$67.43M	4.37	-$137.06M	-$1.95	N/A

Cybin currently has a consensus price target of $48.60, suggesting a potential upside of 312.91%. Zentalis Pharmaceuticals has a consensus price target of $6.75, suggesting a potential upside of 64.23%. Given Cybin's stronger consensus rating and higher possible upside, research analysts plainly believe Cybin is more favorable than Zentalis Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cybin	0 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	3.00
Zentalis Pharmaceuticals	1 Sell rating(s)	4 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.33

Summary

Zentalis Pharmaceuticals beats Cybin on 7 of the 13 factors compared between the two stocks.

How does Zentalis Pharmaceuticals compare to Amphastar Pharmaceuticals?

Amphastar Pharmaceuticals (NASDAQ:AMPH) and Zentalis Pharmaceuticals (NASDAQ:ZNTL) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, earnings, analyst recommendations, media sentiment, dividends and profitability.

Amphastar Pharmaceuticals has a beta of 0.92, meaning that its stock price is 8% less volatile than the broader market. Comparatively, Zentalis Pharmaceuticals has a beta of 1.85, meaning that its stock price is 85% more volatile than the broader market.

65.1% of Amphastar Pharmaceuticals shares are held by institutional investors. 29.6% of Amphastar Pharmaceuticals shares are held by insiders. Comparatively, 3.8% of Zentalis Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Amphastar Pharmaceuticals has higher revenue and earnings than Zentalis Pharmaceuticals. Zentalis Pharmaceuticals is trading at a lower price-to-earnings ratio than Amphastar Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amphastar Pharmaceuticals	$719.89M	1.41	$98.09M	$1.69	14.11
Zentalis Pharmaceuticals	$67.43M	4.37	-$137.06M	-$1.95	N/A

Amphastar Pharmaceuticals has a net margin of 10.76% compared to Zentalis Pharmaceuticals' net margin of 0.00%. Amphastar Pharmaceuticals' return on equity of 14.98% beat Zentalis Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amphastar Pharmaceuticals	10.76%	14.98%	6.96%
Zentalis Pharmaceuticals	N/A	-70.18%	-51.46%

Amphastar Pharmaceuticals presently has a consensus target price of $22.50, suggesting a potential downside of 5.62%. Zentalis Pharmaceuticals has a consensus target price of $6.75, suggesting a potential upside of 64.23%. Given Zentalis Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Zentalis Pharmaceuticals is more favorable than Amphastar Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amphastar Pharmaceuticals	2 Sell rating(s)	6 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.75
Zentalis Pharmaceuticals	1 Sell rating(s)	4 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.33

In the previous week, Amphastar Pharmaceuticals had 2 more articles in the media than Zentalis Pharmaceuticals. MarketBeat recorded 7 mentions for Amphastar Pharmaceuticals and 5 mentions for Zentalis Pharmaceuticals. Amphastar Pharmaceuticals' average media sentiment score of 0.97 beat Zentalis Pharmaceuticals' score of 0.71 indicating that Amphastar Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Amphastar Pharmaceuticals	4 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Zentalis Pharmaceuticals	1 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Amphastar Pharmaceuticals beats Zentalis Pharmaceuticals on 11 of the 16 factors compared between the two stocks.

Get Zentalis Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ZNTL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ZNTL vs. The Competition

Export

Metric	Zentalis Pharmaceuticals	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$270.20M	$12.25B	$7.26B	$12.73B
Dividend Yield	N/A	2.59%	2.53%	8.86%
P/E Ratio	-2.11	787.27	273.29	25.38
Price / Sales	4.37	753.79	613.45	92.55
Price / Cash	N/A	94.80	77.82	52.26
Price / Book	2.06	12.33	12.89	6.14
Net Income	-$137.06M	$2.82B	$3.47B	$349.01M
7 Day Performance	8.16%	2.59%	0.60%	-0.27%
1 Month Performance	-15.78%	6.95%	5.73%	0.68%
1 Year Performance	132.20%	9.45%	25.35%	14.84%

Zentalis Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ZNTL Zentalis Pharmaceuticals	2.7551 of 5 stars	$4.11 +9.0%	$6.75 +64.2%	+140.4%	$270.20M	$67.43M	N/A	160	Positive News Gap Down
PCRX Pacira BioSciences	3.5474 of 5 stars	$24.86 +0.8%	$30.20 +21.5%	-2.1%	$983.39M	$726.41M	71.03	720	Positive News Analyst Upgrade
IVA Inventiva	2.3069 of 5 stars	$4.70 +0.4%	$16.56 +252.2%	-16.1%	$972.07M	$5.07M	N/A	100	Gap Up
ARDX Ardelyx	3.9985 of 5 stars	$3.74 -3.9%	$13.90 +271.7%	-43.0%	$969.34M	$407.32M	N/A	90
HELP Cybin	2.9272 of 5 stars	$13.02 +3.4%	$48.60 +273.3%	N/A	$919.83M	N/A	N/A	50	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ZNTL) was last updated on 9/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Zentalis Pharmaceuticals (ZNTL) Competitors

ZNTL vs. PCRX, IVA, ARDX, HELP, and AMPH

How does Zentalis Pharmaceuticals compare to Pacira BioSciences?

Summary

How does Zentalis Pharmaceuticals compare to Inventiva?

Summary

How does Zentalis Pharmaceuticals compare to Ardelyx?

Summary

How does Zentalis Pharmaceuticals compare to Cybin?

Summary

How does Zentalis Pharmaceuticals compare to Amphastar Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ZNTL vs. The Competition

Zentalis Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Zentalis Pharmaceuticals (ZNTL) Competitors

ZNTL vs. PCRX, IVA, ARDX, HELP, and AMPH

How does Zentalis Pharmaceuticals compare to Pacira BioSciences?

Is PCRX or ZNTL more profitable?

Which has higher earnings & valuation, PCRX or ZNTL?

Do institutionals and insiders hold more shares of PCRX or ZNTL?

Do analysts rate PCRX or ZNTL?

Does the media favor PCRX or ZNTL?

Which has more volatility & risk, PCRX or ZNTL?

Summary

How does Zentalis Pharmaceuticals compare to Inventiva?

Is ZNTL or IVA more profitable?

Do analysts rate ZNTL or IVA?

Which has more risk and volatility, ZNTL or IVA?

Does the media prefer ZNTL or IVA?

Do institutionals & insiders hold more shares of ZNTL or IVA?

Which has better earnings & valuation, ZNTL or IVA?

Summary

How does Zentalis Pharmaceuticals compare to Ardelyx?

Does the media favor ARDX or ZNTL?

Do analysts rate ARDX or ZNTL?

Do insiders and institutionals have more ownership in ARDX or ZNTL?

Which has more risk & volatility, ARDX or ZNTL?

Is ARDX or ZNTL more profitable?

Which has higher valuation and earnings, ARDX or ZNTL?

Summary

How does Zentalis Pharmaceuticals compare to Cybin?

Is HELP or ZNTL more profitable?

Which has more volatility and risk, HELP or ZNTL?

Does the media favor HELP or ZNTL?

Do institutionals and insiders hold more shares of HELP or ZNTL?

Which has stronger valuation and earnings, HELP or ZNTL?

Do analysts recommend HELP or ZNTL?

Summary

How does Zentalis Pharmaceuticals compare to Amphastar Pharmaceuticals?

Which has more risk and volatility, AMPH or ZNTL?

Do insiders and institutionals hold more shares of AMPH or ZNTL?

Which has stronger earnings and valuation, AMPH or ZNTL?

Is AMPH or ZNTL more profitable?

Do analysts prefer AMPH or ZNTL?

Does the media favor AMPH or ZNTL?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ZNTL vs. The Competition

Zentalis Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools